EZH2 mutations are related to low blast percentage in bone marrow and-7/del (7q) in de novo acute myeloid leukemia
The purpose of the present work was to determine the incidence and clinical implications of
somatic EZH2 mutations in 714 patients with de novo acute myelogenous leukemia by …
somatic EZH2 mutations in 714 patients with de novo acute myelogenous leukemia by …
[HTML][HTML] EZH2 mutations and impact on clinical outcome: an analysis in 1,604 patients with newly diagnosed acute myeloid leukemia
The enhancer of zeste homolog 2 (EZH2) is a histone methyltransferase and functional core
subunit of the polycomb repressive complex 2 (PRC2), which is a key epigenetic regulator …
subunit of the polycomb repressive complex 2 (PRC2), which is a key epigenetic regulator …
EZH2, new diagnosis and prognosis marker in acute myeloid leukemia patients
Purpose Acute myeloid leukemia (AML) is a heterogeneous disease. The discovery of novel
discriminative biomarkers remains of utmost value for improving outcome predictions …
discriminative biomarkers remains of utmost value for improving outcome predictions …
Molecular characterization of EZH2 mutant patients with myelodysplastic/myeloproliferative neoplasms
J Rinke, JP Müller, MF Blaess, A Chase… - Leukemia, 2017 - nature.com
Mutations in the epigenetic regulator gene EZH2 are frequently observed in patients with
myelodysplastic/myeloproliferative neoplasms (MDS/MPN; 10–13%) and are associated …
myelodysplastic/myeloproliferative neoplasms (MDS/MPN; 10–13%) and are associated …
Dual roles of EZH2 in acute myeloid leukemia
RC Skoda, J Schwaller - Journal of Experimental Medicine, 2019 - rupress.org
In this issue of JEM, Basheer et al.(https://doi. org/10.1084/jem. 20181276) describe
opposing roles of the epigenetic regulator Ezh2 during initiation and maintenance of acute …
opposing roles of the epigenetic regulator Ezh2 during initiation and maintenance of acute …
A somatic EZH2 mutation in childhood acute myeloid leukemia
T Ernst, A Pflug, J Rinke, J Ernst, U Bierbach, JF Beck… - Leukemia, 2012 - nature.com
10 Stilgenbauer S, Sander S, Bullinger L, Benner A, Leupolt E, Winkler D et al. Clonal
evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations …
evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations …
EZH2 in myeloid malignancies
J Rinke, A Chase, NCP Cross, A Hochhaus, T Ernst - Cells, 2020 - mdpi.com
Our understanding of the significance of epigenetic dysregulation in the pathogenesis of
myeloid malignancies has greatly advanced in the past decade. Enhancer of Zeste Homolog …
myeloid malignancies has greatly advanced in the past decade. Enhancer of Zeste Homolog …
RARA and RARG gene downregulation associated with EZH2 mutation in acute promyelocytic-like morphology leukemia
N Coccaro, A Zagaria, P Orsini, L Anelli, G Tota… - Human Pathology, 2018 - Elsevier
Most acute promyelocytic leukemia (APL) patients express PML-RARA fusion; in rare cases,
RARA is rearranged with partner genes other than PML. To date, only 2 patients presenting …
RARA is rearranged with partner genes other than PML. To date, only 2 patients presenting …
Ezh2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemia
EZH2, a catalytic component of the polycomb repressive complex 2, trimethylates histone H3
at lysine 27 (H3K27) to repress the transcription of target genes. Although EZH2 is …
at lysine 27 (H3K27) to repress the transcription of target genes. Although EZH2 is …
Immunohistochemical loss of enhancer of Zeste Homolog 2 (EZH2) protein expression correlates with EZH2 alterations and portends a worse outcome in …
Abstract EZH2 coding mutation (EZH2 MUT), resulting in loss-of-function, is an independent
predictor of overall survival in MDS. EZH2 function can be altered by other mechanisms …
predictor of overall survival in MDS. EZH2 function can be altered by other mechanisms …